VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
APYXApyx Medical Corporation
$4.50$188M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAPYXCash Flow

Apyx Medical Corporation (APYX) Cash Flow Statement

30Y historyFree accessUpdated daily

Free cash flow remains deeply negative, with a -5.1% FCF margin in 2026Q1, highlighting a structural inability to fund operations internally despite a cash balance of $31.1 million.

APYX Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations-7.87M-8M-18.05M-5.25M-20.28M-10.45M-16.07M-18.48M-21.01M-3.7M-2.84M-5.79M-417K-2.54M165K1.9M-566K-98.33K742.83K2.04M2.99M-189.62K2.04M413.52K73.98K940.78K657.5K530.72K-14.01K-98.79K425.3K
Operating CF Margin %--15.14%-37.52%-10.03%-45.56%-21.54%-57.98%-65.43%-125.92%-9.53%-7.75%-19.6%-1.51%-10.72%0.6%7.47%-2.34%-0.36%2.64%7.09%11.19%-0.94%9.97%2.5%0.59%8.19%6.62%5.53%-0.17%-1.34%5.68%
Operating CF Growth %124.25%55.67%-243.82%74.12%-94.09%34.96%13.04%12.07%-467.25%-30.56%50.97%-1287.53%83.56%-1636.97%-91.3%435.16%-475.6%-113.24%-63.61%-31.64%1674.83%-109.28%394.29%458.96%-92.14%43.08%23.89%3888.18%85.82%-123.23%3302.4%
Net Income-9.17M-11.11M-23.56M-18.85M-23.28M-15.2M-11.91M-19.71M64.01M-5.06M-3.95M-5.37M-17.28M-4.34M617K109K-1.53M595.52K1.83M2.4M2.68M406.21K1.51M681.32K-514.76K784.29K500.63K-2.18M-998.05K99.19K407.3K
Depreciation & Amortization719K655K599K692K890K903K887K754K669K696K734K812K876K827K857K925K1.01M1.05M973.07K770.83K529.26K545.88K395.12K314.68K274.88K524.24K396.81K321.17K787.09K311.14K260.6K
Stock-Based Compensation1.02M2M4.01M5.11M6.7M5.09M4.21M3.58M1.52M871K809K575K388K506K161K132K163K136.38K0000000000000
Deferred Taxes00000000-368K-196K25K-25K3.98M-1.61M210K-76K-974K60.38K754.01K-208.84K00000000008.3K
Other Non-Cash Items2.83M2.04M2.15M2.25M628K603K996K215K-68.45M503K209K-1.62M8.03M912K-154K703K1.15M12.03K165.82K-20.11K509.56K058.61K326.58K367.55K-211.19K02.81M390.1K-63.6K10K
Working Capital Changes-3.4M-1.59M-1.25M5.54M-5.22M-1.84M-10.25M-3.32M-18.4M-516K-664K-157K3.59M1.17M-1.53M104K-371K-1.95M-1.49M-906.93K-735.8K-1.14M78.27K-909.06K-53.68K-156.57K-239.94K-421.09K-193.15K-445.52K-260.9K
Change in Receivables-1.31M-1.32M-2.04M3.97M1.92M-4.9M-558K-3.79M-382K-303K-1.88M-933K-3K884K-658K-126K451K440.42K0000000000000
Change in Inventory-1.72M-1.07M2.26M1.46M-5.57M-2.86M615K-2.37M-881K-870K-379K-102K1.96M-884K287K-719K-822K-1.46M-1.29M-812.13K-612.47K-870.83K249.5K-234.1K-286.7K-407.84K-312.17K-201.23K-24.7K-109.92K-247.8K
Change in Payables275K355K-63K25K67K1.15M-965K1.05M-224K-23K392K-189K494K257K-284K134K362K-727.93K0000000000000
Cash from Investing-1.12M-1.11M-722K6.73M-1.01M-723K-581K60.54M29.3M-624K-286K-921K-630K-588K-753K-542K432K-2.46M-4.51M-1.71M-2.47M-917.05K-314.75K-654.84K-247.17K-519.31K-639.87K-126.73K-443.83K-257.73K156.6K
Capital Expenditures-1.12M-1.11M-722K-533K-1.01M-723K-581K-1.3M-363K-624K-286K-421K-630K-588K-753K-542K-201K-2.47M-4.52M-1.71M-2.47M-910.28K-606.5K-565.91K-220.67K-172.94K-256.08K-126.73K-321.22K-257.72K-456.8K
CapEx % of Revenue2%2.11%1.5%1.02%2.27%1.49%2.1%4.61%2.18%1.6%0.78%1.43%2.28%2.49%2.72%2.13%0.83%9.15%16.1%5.95%9.28%4.5%2.96%3.42%1.77%1.51%2.58%1.32%3.81%3.5%6.1%
Acquisitions0007.41M0195K0091.09M00-500K0000000000000000000
Investments-------------------------------
Other Investing000-147K0-195K0029.66M0000000633K1.23K10.57K00-6.77K291.76K-88.93K-26.5K-346.37K-383.79K0-122.61K-10613.4K
Cash from Financing9.64M9.58M6.75M32.17M217K24K-73K147K-2.49M-179K5.77M12.78M-1.14M6.89M-130K-302K1.72M2.15M2.89M253.9K1.15M107.2K259.37K168.25K-25.96K-121.78K-154.04K-267.6K688.27K283.87K0
Debt Issued (Net)-20K-20K-20K35.04M-148K-238K-369K-60K-2.69M-239K-240K-239K-84K-162K-130K-302K-1.1M2.07M2.66M0-186.46K-31.66K-35.34K-553.46K-31.67K55.86K-33.21K-19.97K-50.01K635K0
Equity Issued (Net)9.63M9.54M7M2.72M365K67K148K0005.83M11.53M259K7.05M009K79K223.03K253.9K1.33M138.86K290.43K251K0-183K-122K-247.63K982.76K0181K
Dividends Paid0000000000000000000000000000000
Share Repurchases0000000000000000000000000-183K-152K-425K000
Other Financing30K60K-235K-5.59M0195K148K207K202K60K184K1.49M-1.32M0002.81M23100004.29K-31.08K5.71K5.37K1.17K0-244.48K-351.13K-181K
Net Change in Cash126K-1K-11.91M33.46M-20.68M-11.04M-16.9M42.22M5.8M-4.51M2.65M6.07M-2.19M3.76M-718K1.05M1.67M-409.62K-970.32K581.87K1.66M-999.48K1.99M-73.07K-199.15K299.69K-136.41K136.4K230.43K-72.66K-44.9K
Free Cash Flow-8.99M-9.12M-18.77M-5.78M-21.29M-11.17M-16.65M-19.78M-21.37M-4.33M-3.12M-6.21M-1.05M-3.12M-588K1.35M-767K-2.56M-3.78M327.97K511.25K-1.1M1.44M-152.39K-146.69K767.84K401.42K404K-335.23K-356.52K-31.5K
FCF Margin %-16.08%-17.25%-39.02%-11.05%-47.83%-23.03%-60.07%-70.04%-128.1%-11.13%-8.53%-21.03%-3.78%-13.2%-2.13%5.33%-3.17%-9.51%-13.45%1.14%1.92%-5.44%7.01%-0.92%-1.18%6.69%4.04%4.21%-3.97%-4.84%-0.42%
FCF Growth %31.64%51.44%-224.61%72.84%-90.57%32.89%15.82%7.48%-393.85%-38.58%49.69%-492.84%66.49%-431.29%-143.39%276.66%70.08%32.19%-1252.66%-35.85%146.48%-176.52%1043.27%-3.89%-119.1%91.28%-0.64%220.51%5.97%-1031.8%91.01%
FCF per Share-0.21-0.22-0.53-0.17-0.62-0.33-0.49-0.58-0.62-0.14-0.11-0.22-0.06-0.18-0.030.08-0.04-0.14-0.220.020.03-0.070.09-0.01-0.010.050.020.03-0.02-0.04-0.00
FCF Conversion (FCF/Net Income)0.98x0.71x0.77x0.28x0.87x0.69x1.35x0.94x-0.33x0.73x0.72x1.08x0.02x0.58x0.27x17.40x0.37x-0.17x0.41x0.85x1.11x-0.47x1.35x0.61x-0.14x1.20x1.31x-0.24x0.01x-1.00x1.04x
Interest Paid3.49M4.64M4.75M1.94M15K10K46K8K104K136K158K000000128K58.46K000000000000
Taxes Paid257K258K382K329K128K111K82K325K13.28M32K27K000000245K135.58K000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Persistent cash burn trajectory

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Remains Highly Disconnected

According to the provided financial data, the relationship between net income and operating cash flow is consistently disjointed, with OCF/NI ratios frequently fluctuating, as seen in the 2025Q4 period where the ratio reached 1.95, suggesting that non-cash items and working capital swings heavily distort reported earnings.

The persistent gap between net losses and operating cash flow suggests that the company's accounting earnings are not currently reflective of its underlying cash generation capabilities. Investors should monitor whether this divergence is driven by recurring non-cash charges or if it indicates a fundamental inability to convert revenue into actual liquidity.

Free Cash Flow Remains Deeply Negative

As reported in recent financial statements, APYX has consistently failed to generate positive free cash flow, with quarterly FCF margins reaching as low as -62.2% in 2024Q1, highlighting a structural inability to fund operations through internal cash generation despite various revenue growth initiatives.

The consistent negative FCF trajectory suggests that the company remains in a cash-consuming phase of its lifecycle, necessitating external financing to sustain operations. This trend warrants further investigation into whether the current cost structure can ever reach a breakeven point without significant scale improvements.

Working Capital Volatility Obscures Performance

Based on reported figures, working capital changes have been highly erratic, swinging from a $2.6M inflow in 2025Q1 to a $2.8M outflow in 2025Q4, which suggests that the company's cash position is highly sensitive to the timing of inventory management and accounts receivable collections.

This volatility in working capital appears to mask the underlying operational cash burn, making it difficult to assess the true efficiency of the company's cash conversion cycle. Analysts should be cautious of relying on short-term cash flow improvements that may be driven by temporary timing differences rather than sustainable operational gains.

Stock-Based Compensation Masks Cash Reality

Analysis of the cash flow statement reveals that stock-based compensation, which reached $1.1M in 2024Q2, serves as a significant non-cash adjustment that effectively subsidizes the company's operating expenses, thereby obscuring the true magnitude of the cash burn required to retain talent.

While SBC is a standard accounting practice, its reliance in this context suggests that the company is using equity to preserve limited cash reserves. Investors should consider the dilutive impact of this strategy alongside the persistent operating losses when evaluating the long-term sustainability of the current capital structure.

APYX — Frequently Asked Questions

Quick answers to the most common questions about buying APYX stock.

How much cash does Apyx Medical Corporation (APYX) generate from operations?

Apyx Medical Corporation (APYX) generated $-8.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Apyx Medical Corporation's free cash flow?

Apyx Medical Corporation (APYX) reported negative free cash flow of $9.1M in 2025, indicating capital requirements exceeded cash from operations.

What is Apyx Medical Corporation's capital expenditure (CapEx)?

Apyx Medical Corporation (APYX) spent $1.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.